Preclinical data have shown that JAB-BX102 has the advantage of dose activity and has potential to benefit patients with solid tumors.
Jacobio has received IND (Investigational New Drug) approval of CD73 mAb JAB-BX102 from the Food and Drug Administration (FDA) of the United States on Oct 15 2021, Jacobio plans to initiate a Phase I/IIa clinical trial in patients with solid tumors.
JAB-BX102 is Jacobio’s first big molecule program entered into the clinical stage. “The landscape of cancer treatment has been more and more complicated, combination therapies between different modalities are needed. Jacobio’s pipeline focuses on the unmet clinical needs and aims to bring hope to more patients through the in-house combination therapies. As an important IO target, CD73 has the potential to be used in combination with Jacobio's in house SHP2 inhibitors, so as to relieve the immunosuppression of tumor microenvironment, stimulate the proliferation and activation of immune effector cells, enhance tumor immunity and play a synergistic role,” said Dr. Yinxiang Wang, Chairman and CEO of Jacobio.
CD73, also known as ecto -5'- nucleotidase, is a kind of cell surface enzyme, which is widely expressed on the surface of skin cells, lymphocytes, Tregs and other cells. CD73 is a key target in the adenosine pathway, and to date, there has been no approved and marketed CD73 targeted drug globally.
Preclinical data have shown that JAB-BX102 has the advantage of dose activity, it has potential to benefit patients with non-small-cell lung cancer, breast cancer and other solid tutors.
Jacobio has more than ten programs targeting five major tumor pathways including SHP2/RAS, I/O, RB, tumor metabolic and c-MYC, and Jacobio has five drugs targeting SHP2, KRAS G12C, BET and CD73 in the clinical stage.
Jacobio(1167.HK) is committed to providing more products and solutions to people's health. Our mission is to provide compelling innovations for creating a pipeline of life-changing medicines. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. The company's R&D centers are located in Beijing, Shanghai and MA, with a platform and expertise in developing allosteric inhibitors against protein tyrosine phosphatase, KRAS and transcriptional factors.